**Press Release**

**Media Contacts:**

**IB Communications**

Tel +44 (0)20 89434685

catalent@ibcomms.agency

**Catalent Announces Collaboration with Galapagos to Further Expand Galapagos’ Decentralized CAR-T Manufacturing Network in the U.S.**

**New Jersey-based manufacturing site to support innovative decentralized approach for improved patient experience**

**January 21 2025 – SOMERSET, NJ –** [Catalent, Inc.](https://tracking.vuelio.co.uk/tracking/click?d=CwxfLh8FGDayEn9_PDJ7srUuqEuSl2XJBNqXXiWyjdaUXsLFSg4sr6xONqDu69kTrVq46iOE1Enq04qWsW5GBCJBigz9Qb11-e649gdcvkljnaRL9U62_84SlkSmpTzauED5SQ9uWOd-5dI-gCejvXs1), a leader in enabling the development and supply of better treatments for patients worldwide, today announced a strategic  collaboration with Galapagos NV (Euronext & NASDAQ: GLPG), a biotechnology company with operations in the U.S. and Europe, to support decentralized manufacturing for clinical studies of GLPG5101, Galapagos’ investigational CAR-T therapy for relapsed/refractory non-Hodgkin lymphoma (NHL) indications. Catalent's commercial cell therapy manufacturing facility in Princeton, New Jersey, will support manufacturing for Galapagos’ upcoming trials in New Jersey, New York, and surrounding areas.

Galapagos’ innovative decentralized manufacturing platform for cell therapies is designed to be deployed close to cancer treatment centers. This class of therapies has shown promising results in patients with NHL, even those who have failed with other therapies. By bringing the manufacturing process closer to patients, Galapagos' platform has the potential to deliver fresh, fit, stem-like early memory cell therapy with a median vein-to-vein time of seven days, thereby avoiding cryopreservation and eliminating the need for bridging therapy.

“Catalent is passionate about increasing patient access to life-changing cell therapies like those being developed by Galapagos,” said Delara Motlagh, at Vice President, Global Cell Therapy and Plasmid DNA at Catalent. “We are delighted by this collaboration to support Galapagos’ decentralized cell therapy approach to bring these pioneering treatments to more patients with certain aggressive forms of NHL in a median vein-to-vein time of seven days. With our highly experienced cell therapy team, state-of-the-art facility network, and central location, we enable timely delivery of these important therapies.”

Financial terms of the agreement are not disclosed.

**ABOUT CATALENT**

Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) whose mission is to develop, manufacture, and supply products that help people live better and healthier lives. Catalent is dedicated to delivering unparalleled service to pharma, biotech, and consumer health customers, supporting product development, launch, and full life-cycle supply. With time-tested experience in development sciences, delivery technologies, and multi-modality manufacturing, Catalent supports the acceleration of development programs and the launch of more than a hundred new products every year. Powered by thousands of scientists and technicians and the latest technology platforms at more than 40 global sites, Catalent supplies billions of doses of life-enhancing and life-saving treatments for patients annually. For more information, visit[www.catalent.com](https://tracking.vuelio.co.uk/tracking/click?d=CwxfLh8FGDayEn9_PDJ7srUuqEuSl2XJBNqXXiWyjdaUXsLFSg4sr6xONqDu69kTe1dLk6W0jE5DoLtcYb517lUTdwLz8jEPCc1I_1O6ZF15YWKH1PofvUkWdWJkWBsV3HHBSdhh0w1rYfkwQvGuNkk1)**.**

**ABOUT GALAPAGOS**

Galapagos is a biotechnology company with operations in the U.S. and Europe dedicated to transforming patient outcomes through life-changing science and innovation for more years of life and quality of life. Focusing on high unmet medical needs, Galapagos synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of best-in-class medicines. With capabilities from lab to patient, including a decentralized cell therapy manufacturing platform, Galapagos is committed to challenging the status quo and delivering results for patients, its employees, and its shareholders. Galapagos’ goal is not just to meet current medical needs but to anticipate and shape the future of healthcare, ensuring that its innovations reach those who need them most. For additional information, please visit [www.glpg.com](https://tracking.vuelio.co.uk/tracking/click?d=9AFN0HAIvfJDcL6GajmLg75s0O6q7z3XJRyExwHpJUcfhH9gtUb1E49KFmjOf_6UI90ckmqZvw98W2KP51o486kdFM6_iEB8pvatRtGe7WhNYpLn6qocYCMi7bkbISPdEIi7zD0g1TssoZOXPZF3OVmOujP4IkuMltpJjcNiRdG_6Iq8Ztm1buoTDiUHgvoS39GTBod-vMIdbgv9VR29FFGgLp27q3O7lStTa0EaA1ILJeEgV1OOkjSWkWGHPJ_swqzUOJsPzDg2kYQk5IE59gdR6f0hhoaLsamjlywBaaW9jNobP6yr0hd_l3PgsOpqpRUgIs6K6BjTg2hHz22TFVpbIR-aeLeKAMcVzVdtphYGA7Gkqg9tzNOxn5QM9vPu33rFDIr7O7aa2QGQAobCw0bAQ_jLutFTp1aWKGRiTVjZuUWs-EbhEOSyDZybGrtSG26dUGHyuyPw3Hl2w8_fv4RV9xzwUdKpVau_SnEQkKgwB1nWb213pnzWMr0gUhW5LMDOnqw0yvwn7XfmU8g2jmzvg6elIGEDntVOpSOlvZ-bncsJNxzPQhq4ZxMqav8DJSKHiHehUIdkxRLRBSL9Xasa3NfTsAGM-fc2F2yEmTGuXycThplg0-20YwrM2Nali0-QDcKs_0Kp1lLOeZdSCNQfhn6blfylHKez6i31sW8S6jOLCt4qaD9PkazAu9-aFg7k5kRhOEKhPXFlSw_GUsKnroUcdOX5H1AX4kqQWnk5WOwbI7UEzKaw_DP2mpd0MnqdR0sM0q5P28IRqNiJgYw4myQc_E-GlK9Gi92SpwJi9N6D9LYwuCPZHhCWv1aTcVvl_gEXu8VyEDVJndaSXAR0AGbflKAprndYJvtnB0p6MfG1c8Bysf-KgZYx92ftnINwXmphfEDDeFEVEyZ99VENLSIoUpwjNIZmvn0ZZI7x2iNithlsWuIRr0XSyGUv7g2) or follow the Company on [LinkedIn](https://tracking.vuelio.co.uk/tracking/click?d=uUL70Hw5kMR1OTnlPjePzkl0rv5-xwALa7h5mlcwAfFZlwNIcyfVCfl2r30RAgpPPvULe43HklTFbUEPf6LHuZ4wWwGNvgEfpLREDDYsK2w0pmbmOCSMJfjBL_77Whmm1DmxrFh6gPWYhzmY5NnbFqna6MEA9SlZbxlR0PvEApErKGLJL8CfOn4B5fsrm7JrfklQArETVgSbqkmXlJiTRqYa6H0BnzlDBTZdf1r0HBKmxlsVXvOu0pHSQlxc_HTfaLX2i5vKwLNjWbwh_X-2zn-etnifOHj7ZGMaDwTLvlAHGbJ028D2nStC9WZtGQyw1y0aNTCdLZV_3ysU0rDzJFKwQo66q5VL1sUne_VbMmfGVYVQMgQ5MTW2bjMSgGCVrW-TP8_9H1DXQExoWdLQ0YToLGQ_NOqgcgPd-fTksSTXWzPtXGV22kZnDqgtr-w0lInsmdmJ_mQynT9na5qPEHju90ZgowEUU2XS_pHk_qDQYIFJlyRJVe7_HyXBwJGTLduXKzyBnzMrWLB6tbXtwzumwKBmXaxApcOodub7PcXztC-XGfcxIngnQWB2P8GJXujhnACyOllHsSud-up8pId7dJ7cBAMxnS9yzfTCevQe1YJgOT1ox_Ldp9CJ3NkqelLWaq_ax1xqYQyuFTmED1dXeRsnk6k99FYyDQIjqjSw7R6zc_--OrPNWsJ-NKNPeT-Gr8qtv2WEgmRkEuyWTSyZ6qNwzXCd9dwtInFo5vDR0RBKGqq-J9x4-gBMytJVI48U-IpNGuRiBXSa1oCTDflzHJwDhfNt-Wc80usXdHJu0a78fFHWSb5JbXDqk03QmWDNiRsiPW1BCnKZ1elm_BW61zCH40-_r_uh_ULTEWsakEb-H1di7IH65H7rgStnZCNRGev9YBO6W7CfzpXP-dfRuMfiTbPol4nHCEZr00S8FUemlgSninVOqCOuc20yyhVSfN2je2EQBRFJ2M6ac_SIwt7kvubOydBoEkxdmRwFGu5I020ZPIRGNvve1PhCD4asMHn3j5J0tUbo14fcjhk1) or [X](https://tracking.vuelio.co.uk/tracking/click?d=9AFN0HAIvfJDcL6GajmLg75s0O6q7z3XJRyExwHpJUcfhH9gtUb1E49KFmjOf_6UnyOCHRxf60mWpDReXLEeHSrR9CJ3scGoSpNZANBRSVMIcYZMc5FdeobXLQQVltdZ514cCxyRJ8rsw4N89S95MCEzt82B65OIrvBw1EMMH83at-IpPEEKc2V3OVDNolQBiWGbgwuhCoEHYcccKuf6LnIiT5d_KyFoSNCrzufvCG__1x8-Jh1Cw216Gqaarf7CD4oaKSDXkN8mmdIfSveaNFgrgimRXfHsHD5iouAWI29aHv7545UXxF6mw8ASxq6KkSiM-fVLN6CDYzGbOBwR53jTNqki64VmMKfxbklLzk1VzK6M5ISPTVjlSVBZB1KZgv4SpfEOR7wfoLyxXe6WUbQV0VGtCqQ_9Oy27WiNOVGkpTGssDK3_zkVELXQ9GPt0sRDzaqJmwFtNh55fvtmxftpXyGnXc-GGXbSS5nX5mHBk0bMNch11d-N662L-6B77GC27sAZM8ZGzxS8dAiVeYPbVqwLH--wjldhiW0FqipA3_Uj7kdVLjxgAkv35MEoYV3OkpaxbWNq9JTWlzpwJ37YCTydaODdm4sZIqZmVVLRINcQOPMvdL4ugUYjQ1PfVBTgegYQ-D3XDrTCSXc0PZi6PF2RPFU1n3V7fJWhHErOjJiPIyTSq7JfAUv_EzgTX8CU00s1uvuoEW6ipVvHl6vNywK8LZQsyk58SuEnrAReaegLd37TGTHqw86fFQe6K4Ao9dhNPLuWj_ai29bvZWE1DYpDffg6PWGUGYQ8MgVzV6sU5FqlgrQX_WuDkrZM72_bdrAeyvSPbHkBdJhisASIaj0J_bp5-XOytqJHHREzsJ_Vx6Cvw_mJ8SiJSwSXz6LjMB2s-B9n6oeCeNtRDiMRidN833zQ8n4hxyWNQ0CS4bLlPeir2O7Ykp3Tsg9O_Q2).